Santhera Pharmaceuticals could soon find out whether its Duchenne muscular dystrophy drug vamorolone will be recommended for EU marketing approval by the European Medicines Agency, paving the way for the product to become the bloc’s first treatment with a full marketing authorization for the condition.
Vamorolone, a first-in-class synthetic steroid, is one of eight new products that are up for an opinion this week on...






